Skip to main content
Journal cover image

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.

Publication ,  Journal Article
Sathornsumetee, S; Desjardins, A; Vredenburgh, JJ; McLendon, RE; Marcello, J; Herndon, JE; Mathe, A; Hamilton, M; Rich, JN; Norfleet, JA ...
Published in: Neuro Oncol
December 2010

Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) signaling are established contributors to malignant glioma (MG) biology. We, therefore, evaluated bevacizumab, a humanized anti-VEGF monoclonal antibody, in combination with the EGFR tyrosine kinase inhibitor erlotinib, in this phase 2 study for recurrent MG patients (www.ClinicalTrials.gov, NCT00671970). Fifty-seven patients (n = 25, glioblastoma [GBM]; n = 32, anaplastic glioma [AG]) were enrolled. The primary endpoint was 6-month progression-free survival (PFS-6). Overall survival (OS), radiographic response, pharmacokinetics, and correlative biomarkers were the secondary endpoints. Patients were stratified based on the concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs). Bevacizumab (10 mg/kg) was given intravenously every 2 weeks. Erlotinib was orally administered daily at 200 mg/day for patients not on EIAEDs and 500 mg/day for patients on EIAEDs. PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively. Twelve (48%) GBM patients and 10 (31%) AG patients achieved a radiographic response. Erlotinib pharmacokinetic exposures were comparable between EIAED and non-EIAED groups. Rash, mucositis, diarrhea, and fatigue were common but mostly grades 1 and 2. Among GBM patients, grade 3 rash, observed in 32%, was associated with survival benefit, whereas elevated hypoxia-inducible factor-2 alpha and VEGF receptor-2 levels were associated with poor survival. Bevacizumab plus erlotinib was adequately tolerated in recurrent MG patients. However, this regimen was associated with similar PFS benefit and radiographic response when compared with other historical bevacizumab-containing regimens.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

December 2010

Volume

12

Issue

12

Start / End Page

1300 / 1310

Location

England

Related Subject Headings

  • Tissue Distribution
  • Survival Rate
  • Quinazolines
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Humans
  • Glioma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J., Herndon, J. E., … Reardon, D. A. (2010). Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol, 12(12), 1300–1310. https://doi.org/10.1093/neuonc/noq099
Sathornsumetee, Sith, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, et al. “Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.Neuro Oncol 12, no. 12 (December 2010): 1300–1310. https://doi.org/10.1093/neuonc/noq099.
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010 Dec;12(12):1300–10.
Sathornsumetee, Sith, et al. “Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.Neuro Oncol, vol. 12, no. 12, Dec. 2010, pp. 1300–10. Pubmed, doi:10.1093/neuonc/noq099.
Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010 Dec;12(12):1300–1310.
Journal cover image

Published In

Neuro Oncol

DOI

EISSN

1523-5866

Publication Date

December 2010

Volume

12

Issue

12

Start / End Page

1300 / 1310

Location

England

Related Subject Headings

  • Tissue Distribution
  • Survival Rate
  • Quinazolines
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Recurrence, Local
  • Middle Aged
  • Male
  • Humans
  • Glioma